Isansys Lifecare, the UK-based digital healthcare company and developer of the world’s most advanced patient monitoring platform, Patient Status Engine, announced the results of a study pointing to a new pathway for managing patients with advanced liver disease based on new methods employing data-driven biomarkers. Isansys is a former finalist of the IOT/WT Innovation World Cup® and speaker and exhibitor of the WT | Wearable Technologies Conference Series.
The team recruited 111 patients for this collaborative study between the University College London Royal Free Hospital, UK, and the University of Bonn, Germany. The results showed a significant reduction in heart rate variability is a feature of acute decompensation of cirrhosis and, remarkably, predicts 90-day mortality in these patients, reports Isansys.
“The Patient Status Engine is more than a remote patient monitoring platform. It is able to directly produce the most complete and accurate physiological data sets outside an intensive care unit, for all patients including those at home. These data sets are the basic requirements for transformative new ways of diagnosing and managing patients as AI and deep learning methods become more widely used in healthcare,” said Keith Errey, CEO of Isansys.
A preliminary study showed that the company’s Patient Status Engine and Lifetouch sensor are ideal for remote monitoring of patients. The researchers used it to create a baseline heart rate variability (HRV) data set from a group of healthy volunteers. They then used the Lifetouch to assess HRV remotely and non-invasively on patients admitted to the Royal Free Hospital with an acute decompensation (a significant deterioration) of advanced cirrhosis.
The results concluded that continuous, wireless monitoring of HRV is feasible in patients with advanced liver disease. The study also supported the hypothesis of both hospital teams that reduced HRV, correlates with severity of liver decompensation, facilitating the identification of high-risk patients, and allowing for timely interventions. In light of these findings, the study suggests the future potential for such continuous monitoring and the prospective health economic benefit of measuring HRV remotely.
“Traditional ECG measurement of HRV encompasses short-term 5-minute ECG segments being interpreted separately as reflecting HRV in that specific time window, under stable physiological conditions. The Lifetouch system by contrast, not only facilitates continuous monitoring irrespective of the individuals’ daily activity or physical ill-health but also helps negate the short coming of limited ECG time capture which make further interpretation difficult. Using the remote monitoring device, we were able to interpret HRV in all monitored in-patients with acute decompensation,” the report concluded.